PepGen advances Phase 2 study with 10 mg/kg DM1 cohort under way
PepGen announced positive data from the 5 mg/kg cohort of its Phase 2 FREEDOM2 MAD study for PGN-EDODM1, a treatment for myotonic dystrophy type 1 (DM1). These results support the ongoing evaluation of the 10 mg/kg cohort, with data expected in the latter half of 2026. The company is also scheduled to discuss these developments in an upcoming webcast and recently participated in the MDA2026 conference.
How this was made

The 30-second read
Why it matters
Positive trial data can boost investor confidence and stock valuation, but market reaction depends on data robustness and timing.
Market read
The news is relevant to biotech investors, particularly those interested in gene therapy and neuromuscular disorder treatments.
What to watch
Regulatory hurdles or funding issues could impact the company's progress regardless of trial data.
Background
PepGen is developing therapies for neuromuscular disorders, with PGN-EDODM1 showing promise in early trials.
Ticker impact
The news pertains to PepGen's ongoing Phase 2 clinical trial for DM1, indicating potential positive developments for the company's stock.
Moderate upward movement expected upon positive data release, with potential for short-term gains.
Clinical trial progress can influence stock prices; however, the impact depends on the magnitude of the data and market perception.
Market effects
Advancement in DM1 treatments may positively influence the biotech sector focused on neuromuscular disorders.
Limited regional impact; primarily relevant to biotech investors and stakeholders.
Moderate; reflects ongoing innovation in gene and molecular therapies.
Counterpoint
Negative trial results or delays could lead to stock declines, offsetting potential gains.
Key entities
- CompanyPepGen
Biotech firm focused on gene therapy for neuromuscular diseases.




